Skip to main navigation
Theratechnologies Inc. Theratechnologies Inc.

    About

  • About
    • About Us
    • Board of Directors
    • Leadership Team
    • Scientific Consultants & Advisors
    • Awards
  • Medicines & Pipeline

  • Medicines & Pipeline
    • Medicines
      • Trogarzo®
      • EGRIFTA SV®
    • Pipeline & Science
      • HIV
        • F8 in HIV-Associated Excess Abdominal Fat
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Hepatology
        • Tesamorelin for the Potential Treatment of NASH
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Oncology
        • SORT1+ Technology™
        • TH1902
        • Scientific Papers
        • Clinical Trials
        • Patient Information
      • Expanded Access Policy
      • Grants/ISRs/IITs
  • IR Nav

  • Investors
    • Overview
    • News, Events & Presentations
      • Press Releases
      • Company Announcements
      • Events
      • Corporate Presentations
    • Stock Information
      • Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financial Information
      • SEC Filings
      • SEDAR Filings
      • Financial Reports
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership Team
      • Committee Composition
    • Investor Resources
      • Contact IR
      • FAQs
  • Corporate Responsibility

  • Corporate Responsibility
  • Careers

  • Careers
  • Contact Us

  • Contact Us
  • en
    • en
    • fr
  • btn Alerts

  • Sign up for Email Alerts

Social icons

Press Releases

Investors

IR Nav

  • Overview
  • News, Events & Presentations
    • Press Releases
    • Company Announcements
    • Events
    • Corporate Presentations
  • Stock Information
    • Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • SEDAR Filings
    • Financial Reports
  • Corporate Governance
    • Documents & Charters
    • Board of Directors
    • Leadership Team
    • Committee Composition
  • Investor Resources
    • Contact IR
    • FAQs

Stock

Prices shown in CAD

Mar 25, 2023 12:30 AM EDT

btn Stock

Learn More

IR Tools

  • Email Alerts
  • Contact IR
  • RSS Feeds

Press Releases

Latest

Mar 14, 2023
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
news
Press Releases
Mar 14, 2023
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
Mar 07, 2023
Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price
Feb 28, 2023
Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022
Feb 28, 2023
Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
Feb 22, 2023
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
Feb 16, 2023
Theratechnologies Announces Path to Resume TH1902 Clinical Development
Feb 14, 2023
Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
Jan 04, 2023
Open Letter to Shareholders from CEO Paul Levesque
Dec 01, 2022
Theratechnologies Announces Update from Ongoing TH1902 Study
Oct 26, 2022
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page ›
  • Last page »
Displaying 1 - 10 of 305

Headquarters

Theratechnologies inc.
2015 Peel Street, 11th Floor
Montréal, Québec
Canada H3A 1T8
Phone: 514 336-7800
Fax: 514 331-9691

European Headquarters

Theratechnologies Europe Limited
2 Hume Street, 4th floor
Dublin 2
Ireland D02 DV24
Phone: +353 1 215 0650
europe@theratech.com

Investor Relations

Elif McDonald
Senior Director, Investor Relations
Phone: +1-438-315-8563
ir@theratech.com

US Headquarters

Theratechnologies U.S., Inc.
101 Hudson Street
21st Floor
Jersey City, New Jersey 07302

Main Nav

  • Home
  • About
  • Medicines & Pipeline
  • Investors
  • Corporate Responsibility
  • Careers
  • Contact Us
©2023 - Theratechnologies Inc.

Legal Nav

  • Terms of Use
  • Privacy

Search

Theratechnologies